MedTrace Logo

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

NCT03006562 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 501

Last updated 2020-08-05

Study results available
· View outcomes & findings →

Summary

The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous thromboembolism (VTE) after radical prostatectomy (RP).

Conditions

Interventions

DRUG

Subcutaneous Heparin

5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.

Sponsors & Collaborators

Principal Investigators

  • Mohamad E Allaf, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-11-01
Completion
2019-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03006562 on ClinicalTrials.gov